NUTRACEUTICALS IN CANCER THERAPY CONFERENCE


Nutraceuticals in Cancer Therapy Conference is one of the leading research topics in the international research conference domain. Nutraceuticals in Cancer Therapy is a conference track under the Nutrition and Food Engineering Conference which aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nutrition and Food Engineering.

internationalscience.net provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of (Nutrition and Food Engineering).

Nutraceuticals in Cancer Therapy is not just a call for academic papers on the topic; it can also include a conference, event, symposium, scientific meeting, academic, or workshop.

You are welcome to SUBMIT your research paper or manuscript to Nutraceuticals in Cancer Therapy Conference Track will be held at “Nutrition and Food Engineering Conference in Istanbul, Turkey in June 2020” - “Nutrition and Food Engineering Conference in Stockholm, Sweden in July 2020” - “Nutrition and Food Engineering Conference in Zürich, Switzerland in September 2020” - “Nutrition and Food Engineering Conference in New York, United States in November 2020” .

Nutraceuticals in Cancer Therapy is also a leading research topic on Google Scholar, Semantic Scholar, Zenedo, OpenAIRE, BASE, WorldCAT, Sherpa/RoMEO, Elsevier, Scopus, Web of Science.

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

JUNE 25 - 26, 2020
ISTANBUL, TURKEY

  • Abstracts/Full-Text Paper Submission Deadline March 14, 2019
  • Notification of Acceptance/Rejection Deadline March 28, 2019
  • Final Paper and Early Bird Registration Deadline May 26, 2020
  • CONFERENCE CODE: 20NFE06TR
  • One Time Submission Deadline Reminder

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

JULY 14 - 15, 2020
STOCKHOLM, SWEDEN

  • Abstracts/Full-Text Paper Submission Deadline March 14, 2019
  • Notification of Acceptance/Rejection Deadline March 28, 2019
  • Final Paper and Early Bird Registration Deadline June 11, 2020
  • CONFERENCE CODE: 20NFE07SE
  • One Time Submission Deadline Reminder

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

SEPTEMBER 16 - 17, 2020
ZÜRICH, SWITZERLAND

  • Abstracts/Full-Text Paper Submission Deadline March 14, 2019
  • Notification of Acceptance/Rejection Deadline March 28, 2019
  • Final Paper and Early Bird Registration Deadline August 13, 2020
  • CONFERENCE CODE: 20NFE09CH
  • One Time Submission Deadline Reminder

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

NOVEMBER 05 - 06, 2020
NEW YORK, UNITED STATES

  • Abstracts/Full-Text Paper Submission Deadline March 14, 2019
  • Notification of Acceptance/Rejection Deadline March 28, 2019
  • Final Paper and Early Bird Registration Deadline October 05, 2020
  • CONFERENCE CODE: 20NFE11US
  • One Time Submission Deadline Reminder
FINISHED

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

NOVEMBER 21 - 22, 2019
PARIS, FRANCE

  • CONFERENCE CODE: 19NFE11FR
FINISHED

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

JANUARY 21 - 22, 2020
LONDON, UNITED KINGDOM

  • CONFERENCE CODE: 20NFE01GB
FINISHED

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

MARCH 26 - 27, 2020
TOKYO, JAPAN

  • CONFERENCE CODE: 20NFE03JP
FINISHED

. INTERNATIONAL NUTRITION AND FOOD ENGINEERING CONFERENCE

MAY 13 - 14, 2020
AMSTERDAM, NETHERLANDS

  • CONFERENCE CODE: 20NFE05NL

Nutrition and Food Engineering Conference Call For Papers are listed below:

Previously Published Papers on "Nutraceuticals in Cancer Therapy Conference"

  • Automatic Staging and Subtype Determination for Non-Small Cell Lung Carcinoma Using PET Image Texture Analysis
    Authors: Seyhan Karaçavuş, Bülent Yılmaz, Ömer Kayaaltı, Semra İçer, Arzu Taşdemir, Oğuzhan Ayyıldız, Kübra Eset, Eser Kaya, Keywords: Cancer stage, cancer cell type, non-small cell lung carcinoma, PET, texture analysis. DOI:10.5281/zenodo.1129860 Abstract: In this study, our goal was to perform tumor staging and subtype determination automatically using different texture analysis approaches for a very common cancer type, i.e., non-small cell lung carcinoma (NSCLC). Especially, we introduced a texture analysis approach, called Law’s texture filter, to be used in this context for the first time. The 18F-FDG PET images of 42 patients with NSCLC were evaluated. The number of patients for each tumor stage, i.e., I-II, III or IV, was 14. The patients had ~45% adenocarcinoma (ADC) and ~55% squamous cell carcinoma (SqCCs). MATLAB technical computing language was employed in the extraction of 51 features by using first order statistics (FOS), gray-level co-occurrence matrix (GLCM), gray-level run-length matrix (GLRLM), and Laws’ texture filters. The feature selection method employed was the sequential forward selection (SFS). Selected textural features were used in the automatic classification by k-nearest neighbors (k-NN) and support vector machines (SVM). In the automatic classification of tumor stage, the accuracy was approximately 59.5% with k-NN classifier (k=3) and 69% with SVM (with one versus one paradigm), using 5 features. In the automatic classification of tumor subtype, the accuracy was around 92.7% with SVM one vs. one. Texture analysis of FDG-PET images might be used, in addition to metabolic parameters as an objective tool to assess tumor histopathological characteristics and in automatic classification of tumor stage and subtype.
  • Biomolecules Based Microarray for Screening Human Endothelial Cells Behavior
    Authors: Adel Dalilottojari, Bahman Delalat, Frances J. Harding, Michaelia P. Cockshell, Claudine S. Bonder, Nicolas H. Voelcker, Keywords: Cardiovascular disease, cell microarray platform, cell therapy, endothelial progenitor cells, high throughput screening. DOI:10.5281/zenodo.1128253 Abstract: Endothelial Progenitor Cell (EPC) based therapies continue to be of interest to treat ischemic events based on their proven role to promote blood vessel formation and thus tissue re-vascularisation. Current strategies for the production of clinical-grade EPCs requires the in vitro isolation of EPCs from peripheral blood followed by cell expansion to provide sufficient quantities EPCs for cell therapy. This study aims to examine the use of different biomolecules to significantly improve the current strategy of EPC capture and expansion on collagen type I (Col I). In this study, four different biomolecules were immobilised on a surface and then investigated for their capacity to support EPC capture and proliferation. First, a cell microarray platform was fabricated by coating a glass surface with epoxy functional allyl glycidyl ether plasma polymer (AGEpp) to mediate biomolecule binding. The four candidate biomolecules tested were Col I, collagen type II (Col II), collagen type IV (Col IV) and vascular endothelial growth factor A (VEGF-A), which were arrayed on the epoxy-functionalised surface using a non-contact printer. The surrounding area between the printed biomolecules was passivated with polyethylene glycol-bisamine (A-PEG) to prevent non-specific cell attachment. EPCs were seeded onto the microarray platform and cell numbers quantified after 1 h (to determine capture) and 72 h (to determine proliferation). All of the extracellular matrix (ECM) biomolecules printed demonstrated an ability to capture EPCs within 1 h of cell seeding with Col II exhibiting the highest level of attachment when compared to the other biomolecules. Interestingly, Col IV exhibited the highest increase in EPC expansion after 72 h when compared to Col I, Col II and VEGF-A. These results provide information for significant improvement in the capture and expansion of human EPC for further application.
  • Prophylactic Effects of Dairy Kluyveromyces marxianus YAS through Overexpression of BAX, CASP 3, CASP 8 and CASP 9 on Human Colon Cancer Cell Lines
    Authors: Amir Saber Gharamaleki, Beitollah Alipour, Zeinab Faghfoori, Ahmad YariKhosroushahi, Keywords: Anticancer, anti-proliferative, apoptosis, cytotoxicity, yeast. DOI:10.5281/zenodo.1112047 Abstract: Colorectal cancer (CRC) is one of the most prevalent cancers and intestinal microbial community plays an important role in colorectal tumorigenesis. Probiotics have recently been assessed as effective anti-proliferative agents and thus this study was performed to examine whether CRC undergo apoptosis by treating with isolated Iranian native dairy yeast, Kluyveromyces marxianus YAS, secretion metabolites. The cytotoxicity assessments on cells (HT-29, Caco-2) were accomplished through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as well as qualitative DAPI (4',6-diamidino-2-phenylindole staining) and quantitative (flow cytometry assessments) evaluations of apoptosis. To evaluate the main mechanism of apoptosis, Real time PCR method was applied. Kluyveromyces marxianus YAS secretions (IC50) showed significant cytotoxicity against HT-29 and Caco-2 cancer cell lines (66.57 % and 66.34 % apoptosis) similar to 5-Fluorouracil (5-FU) while apoptosis only was developed in 27.57 % of KDR normal cells. The prophylactic effects of Kluyveromyces marxianus (PTCC 5195), as a reference yeast, was not similar to Kluyveromyces marxianus YAS indicating strain dependency of bioactivities on CRC disease prevention. Based on real time PCR results, the main cytotoxicity is related to apoptosis phenomenon and the core related mechanism is depended on the overexpression of BAX, CASP 9, CASP 8 and CASP 3 inducing apoptosis genes. However, several investigations should be conducted to precisely determine the effective compounds to be used as anticancer therapeutics in the future.
  • Tomato Lycopene: Functional Proprieties and Health Benefits
    Authors: C. S. Marques, M. J. Reis Lima, J. Oliveira, E. Teixeira-Lemos, Keywords: Tomato, lycopene, bioavailability, functional foods, carotenoids, cancer and antioxidants. DOI:10.5281/zenodo.1109297 Abstract: The growing concerns for physical wellbeing and health have been reflected in the way we choose food in our table. Nowadays, we are all more informed consumers and choose healthier foods. On the other hand, stroke, cancer and atherosclerosis may be somehow minimized by the intake of some bioactive compounds present in food, the so-called nutraceuticals and functional foods. The aim of this work was to make a revision of the published studies about the effects of some bioactive compounds, namely lycopene in human health, in the prevention of diseases, thus playing the role of a functional food. Free radical in human body can induce cell damage and consequently can be responsible for the development of some cancers and chronic diseases. Lycopene is one of the most powerful antioxidants known, being the predominant carotenoid in tomato. The respective chemistry, bioavailability, and its functional role in the prevention of several diseases will be object of this work. On the other hand, the inclusion of lycopene in some foods can also be made by biotechnology and represents a way to recover the wastes in the tomato industry with nutritional positive effects in health.
  • Chemical Composition of Essential Oil and in vitro Antibacterial and Anticancer Activity of the Hydroalcolic Extract from Coronilla varia
    Authors: Dehpour A. A., Eslami B., Rezaie S., Hashemian S. F., Shafie F., Kiaie M., Keywords: Coronilla varia, Essential oil, Antibacterial, Anticancer, HeLa cell line. DOI:10.5281/zenodo.1108875 Abstract: The aims of study were investigation on chemical composition essential oil and the effect of extract of Coronilla varia on antimicrobial and cytotoxicity activity. The essential oils of Coronilla varia is obtained by hydrodistillation and analyzed by (GC/MS) for determining their chemical composition and identification of their components. Antibacterial activity of plant extract was determined by disc diffusion method and anticancer activity measured by MTT assay. The major components in essential oil were Caryophyllene Oxide (60.19%), Alphacadinol (4.13%) and Homoadantaneca Robexylic Acid (3.31%). The extracts from Coronilla varia had interesting activity against Proteus mirabilis in the concentration of 700 μg/disc and did not show any activity against Staphylococus aureus, Bacillus subtillis, Klebsiella pneumonia and Entrobacter cloacae. The positive control, Ampicillin, Chloramphenicol and Cenphalothin had shown zone of inhibition resistant all bacteria. The ethanol extract of Corohilla varia inhibited on MCF7 cell lines. IC50 0.6(mg/ml) was the optimum concentration of extract from Coronilla varia inhibition of cell line growth. The MCF7 cancer cell line and Proteus mirabilis were more sensitive to Coronilla varia ethanol extract.
  • Bifidobacterium lactis Fermented Milk Was Not Effective for Helicobacter pylori Eradication: A Prospective, Randomized, Double-Blind, Controlled Study
    Authors: R. C. Barbuti, M. N. Oliveira, N. P. Perina, C. Haro, P. Bosch, C. S. Bogsan, J. N. Eisig, T. Navarro-Rodriguez, Keywords: Antibacterial Therapy, Bifidobacteria Fermented milk, Helicobacter pylori, probiotics. DOI:10.5281/zenodo.1099690 Abstract: The management of Helicobacter pylori (H. pylori) eradication is still a matter of discussion, full effectiveness is rarely achieved, and it has many adverse effects. The use of probiotics may be associated with better eradication rates and possibly prevention of adverse events due to antibiotic therapy. The present clinical study was undertaken to evaluate the efficacy of a specially designed fermented milk product, containing Bifidobacterium lactis B420, on the eradication of H. pylori infection in a prospective, randomized, double-blind, controlled study in humans. Four test fermented milks (FM) were specially designed in which counts of viable cells in all products were 10^10 Log CFU. 100 mL-1 for Bifidobacterium lactis - Bifidobacterium species 420. 190 subjects infected with H. pylori, with previous diagnosis of functional dyspepsia according to Rome III criteria entered the study. Bifidobacterium lactis B420, administered twice a day for 90 days was not able to eradicate H. pylori in Brazilian patients with functional dyspepsia.
  • Periodontal Disease or Cement Disease? New Frontier in the Treatment of Periodontal Disease in Dogs
    Authors: C. Gallottini, W. Di Mari, A. Amaddeo, K. Barbaro, A. Dolci, G. Dolci, L. Gallottini, G. Barraco, S. Eramo, Keywords: Nanoidroxiaphatite, Parodontal Disease, Rigenerative Therapy. DOI:10.5281/zenodo.1092864 Abstract: A group of 10 dogs (group A) with Periodontal Disease in the third stage, were subjected to regenerative therapy of periodontal tissues, by use of nano hydroxy apatite (NHA). These animals induced by general anesthesia, where treated by ultrasonic scaling, root planning, and at the end by a mucogingival flap in which it was applied NHA. The flap was closed and sutured with simple steps. Another group of 10 dogs (group B), control group, was treated only by scaling and root planning. No patient was subjected to antibiotic therapy. After three months, a check was made by inspection of the oral cavity, radiography and bone biopsy at the alveolar level. Group A showed a total restitutio ad integrum of the periodontal structures, and in group B still mild gingivitis in 70% of cases and 30% of the state remains unchanged. Numerous experimental studies both in animals and humans have documented that the grafts of porous hydroxyapatite are rapidly invaded by fibrovascular tissue which is subsequently converted into mature lamellar bone tissue by activating osteoblast. Since we acted on the removal of necrotic cementum and rehabilitating the root tissue by polishing without intervention in the ligament but only on anatomical functional interface of cement-blasts, we can connect the positive evolution of the clinical-only component of the cement that could represent this perspective, the only reason that Periodontal Disease become a Cement Disease, while all other clinical elements as nothing more than a clinical pathological accompanying.
  • Automatic Detection of Breast Tumors in Sonoelastographic Images Using DWT
    Authors: A. Sindhuja, V. Sadasivam, Keywords: Breast Cancer, Segmentation, Sonoelastography, Tumor Detection. DOI:10.5281/zenodo.1089054 Abstract: Breast Cancer is the most common malignancy in women and the second leading cause of death for women all over the world. Earlier the detection of cancer, better the treatment. The diagnosis and treatment of the cancer rely on segmentation of Sonoelastographic images. Texture features has not considered for Sonoelastographic segmentation. Sonoelastographic images of 15 patients containing both benign and malignant tumorsare considered for experimentation.The images are enhanced to remove noise in order to improve contrast and emphasize tumor boundary. It is then decomposed into sub-bands using single level Daubechies wavelets varying from single co-efficient to six coefficients. The Grey Level Co-occurrence Matrix (GLCM), Local Binary Pattern (LBP) features are extracted and then selected by ranking it using Sequential Floating Forward Selection (SFFS) technique from each sub-band. The resultant images undergo K-Means clustering and then few post-processing steps to remove the false spots. The tumor boundary is detected from the segmented image. It is proposed that Local Binary Pattern (LBP) from the vertical coefficients of Daubechies wavelet with two coefficients is best suited for segmentation of Sonoelastographic breast images among the wavelet members using one to six coefficients for decomposition. The results are also quantified with the help of an expert radiologist. The proposed work can be used for further diagnostic process to decide if the segmented tumor is benign or malignant.
  • A Pairwise-Gaussian-Merging Approach: Towards Genome Segmentation for Copy Number Analysis
    Authors: Chih-Hao Chen, Hsing-Chung Lee, Qingdong Ling, Hsiao-Jung Chen, Sun-Chong Wang, Li-Ching Wu, H.C. Lee, Keywords: Cancer, pathogenesis, chromosomal aberration, copy number variation, segmentation analysis. DOI:10.5281/zenodo.1082655 Abstract: Segmentation, filtering out of measurement errors and identification of breakpoints are integral parts of any analysis of microarray data for the detection of copy number variation (CNV). Existing algorithms designed for these tasks have had some successes in the past, but they tend to be O(N2) in either computation time or memory requirement, or both, and the rapid advance of microarray resolution has practically rendered such algorithms useless. Here we propose an algorithm, SAD, that is much faster and much less thirsty for memory – O(N) in both computation time and memory requirement -- and offers higher accuracy. The two key ingredients of SAD are the fundamental assumption in statistics that measurement errors are normally distributed and the mathematical relation that the product of two Gaussians is another Gaussian (function). We have produced a computer program for analyzing CNV based on SAD. In addition to being fast and small it offers two important features: quantitative statistics for predictions and, with only two user-decided parameters, ease of use. Its speed shows little dependence on genomic profile. Running on an average modern computer, it completes CNV analyses for a 262 thousand-probe array in ~1 second and a 1.8 million-probe array in 9 seconds
  • HIV Treatment Planning on a case-by-CASE Basis
    Authors: Marios M. Hadjiandreou, Raul Conejeros, Ian Wilson, Keywords: AIDS, chemotherapy, mathematical modeling, optimal control, progression. DOI:10.5281/zenodo.1071055 Abstract: This study presents a mathematical modeling approach to the planning of HIV therapies on an individual basis. The model replicates clinical data from typical-progressors to AIDS for all stages of the disease with good agreement. Clinical data from rapid-progressors and long-term non-progressors is also matched by estimation of immune system parameters only. The ability of the model to reproduce these phenomena validates the formulation, a fact which is exploited in the investigation of effective therapies. The therapy investigation suggests that, unlike continuous therapy, structured treatment interruptions (STIs) are able to control the increase in both the drug-sensitive and drug-resistant virus population and, hence, prevent the ultimate progression from HIV to AIDS. The optimization results further suggest that even patients characterised by the same progression type can respond very differently to the same treatment and that the latter should be designed on a case-by-case basis. Such a methodology is presented here.